A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Buprenorphine/samidorphan (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Acronyms FORWARD-2
- Sponsors Alkermes plc
- 14 Mar 2017 According to eudra record, this trial was completed in Bulgaria.
- 12 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2016 This trial has been completed in Poland.